Europe's Med Tech Advantage Is Real, But Only If You Build It Right with Tatiana Lobanov-Rostovsky
In this episode of the Crux of MedTech, Henry Norton is joined by Tatiana Lobanov-Rostovsky, Investor at Oxford Science Enterprises, the independent, billion-pound investment company built in partnership with the University of Oxford. With a background in neuroscience, Healthcare M&A at Rothschild & Co, and hands-on experience inside a biotech startup, Tatiana brings a rare view across the full lifecycle of medtech company building.
From the Europe vs US debate to why most companies fail not in R&D but in commercial and what the best founders do differently from day one, this is a candid…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.